Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Study Population and Data Source
2.3. Data Collection
2.3.1. Patient Characteristics
2.3.2. Tumour Outcomes
2.3.3. Toxicity
2.3.4. Malnutrition: Clinical Data
2.4. Statistical Analyses
3. Results
3.1. Patient Characteristics
3.1.1. General Characteristics
3.1.2. Nutritional Status at Baseline
3.1.3. Dietary Management
3.2. Association between Nutritional Status and Clinical Characteristics
3.3. Influence of Nutritional Status on Immunotherapy Efficacy
3.4. Influence of Nutritional Status on Immunotherapy Tolerance
3.5. Influence of Nutritional Status on Survival
3.6. Nutritional Assessment, Weight Changes during Treatment
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Horn, L.; Spigel, D.R.; Vokes, E.E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 2017, 35, 3924–3933. [Google Scholar] [CrossRef] [PubMed]
- Temel, J.S.; Greer, J.A.; Goldberg, S.; Vogel, P.D.; Sullivan, M.; Pirl, W.F.; Lynch, T.J.; Christiani, D.C.; Smith, M.R. A Structured Exercise Program for Patients with Advanced Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2010, 4, 595–601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lutz, S.; Norrell, R.; Bertucio, C.; Kachnic, L.; Johnson, C.; Arthur, D.; Schwarz, M.; Palardy, G. Symptom Frequency and Severity in Patients with Metastatic or Locally Recurrent Lung Cancer: A Prospective Study Using the Lung Cancer Symptom Scale in a Community Hospital. J. Palliat. Med. 2001, 4, 157–165. [Google Scholar] [CrossRef] [PubMed]
- Planchard, D.; Popat, S.; Kerr, K.; Novello, S.; Smit, E.F.; Faivre-Finn, C.; Mok, T.S.; Reck, M.; Van Schil, P.E.; Hellmann, M.D.; et al. Correction to: “Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up”. Ann. Oncol. 2019, 30, 863–870. [Google Scholar] [CrossRef]
- Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [Google Scholar] [CrossRef]
- Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 123–135. [Google Scholar] [CrossRef] [Green Version]
- Pamoukdjian, F.; Bouillet, T.; Lévy, V.; Soussan, M.; Zelek, L.; Paillaud, E. Prevalence and Predictive Value of Pre-Therapeutic Sarcopenia in Cancer Patients: A Systematic Review. Clin. Nutr. 2018, 37, 1101–1113. [Google Scholar] [CrossRef]
- Kiss, N. Nutrition Support and Dietary Interventions for Patients with Lung Cancer: Current Insights. Lung Cancer 2016, 7, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Raynard, B.; Pigneur, F.; Di Palma, M.; Deluche, E.; Goldwasser, F. The Prevalence of CT-Defined Low Skeletal Muscle Mass in Patients with Metastatic Cancer: A Cross-Sectional Multicenter French Study (the SCAN Study). Support. Care Cancer 2022, 30, 3119–3129. [Google Scholar] [CrossRef]
- Martin, L.; Senesse, P.; Gioulbasanis, I.; Antoun, S.; Bozzetti, F.; Deans, C.; Strasser, F.; Thoresen, L.; Jagoe, R.T.; Chasen, M.; et al. Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss. J. Clin. Oncol. 2015, 33, 90–99. [Google Scholar] [CrossRef] [PubMed]
- Lim, S.; Brown, J.L.; Washington, T.A.; Greene, N.P. Development and Progression of Cancer Cachexia: Perspectives from Bench to Bedside. Sports Med. Health Sci. 2020, 2, 177–185. [Google Scholar] [CrossRef] [PubMed]
- Ni, J.; Zhang, L. Cancer Cachexia: Definition, Staging, and Emerging Treatments. Cancer Manag. Res. 2020, 12, 5597–5605. [Google Scholar] [CrossRef] [PubMed]
- Bargetzi, L.; Brack, C.; Herrmann, J.; Bargetzi, A.; Hersberger, L.; Bargetzi, M.; Kaegi-Braun, N.; Tribolet, P.; Gomes, F.; Hoess, C.; et al. Nutritional Support during the Hospital Stay Reduces Mortality in Patients with Different Types of Cancers: Secondary Analysis of a Prospective Randomized Trial. Ann. Oncol. 2021, 32, 1025–1033. [Google Scholar] [CrossRef]
- Heudel, P.; Livartowski, A.; Arveux, P.; Willm, E.; Jamain, C. ConSoRe: Un outil permettant de rentrer dans le monde du big data en santé. Bull. Cancer 2016, 103, 949–950. [Google Scholar] [CrossRef]
- Forrest, L.M.; McMillan, D.C.; McArdle, C.S.; Angerson, W.J.; Dunlop, D.J. Evaluation of Cumulative Prognostic Scores Based on the Systemic Inflammatory Response in Patients with Inoperable Non-Small-Cell Lung Cancer. Br. J. Cancer 2003, 89, 1028–1030. [Google Scholar] [CrossRef] [Green Version]
- McMillan, D.C. The Systemic Inflammation-Based Glasgow Prognostic Score: A Decade of Experience in Patients with Cancer. Cancer Treat. Rev. 2013, 39, 534–540. [Google Scholar] [CrossRef]
- Gibney, G.T.; Weiner, L.M.; Atkins, M.B. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Lancet Oncol. 2016, 17, e542–e551. [Google Scholar] [CrossRef] [Green Version]
- Hopkins, A.M.; Rowland, A.; Kichenadasse, G.; Wiese, M.D.; Gurney, H.; McKinnon, R.A.; Karapetis, C.S.; Sorich, M.J. Predicting Response and Toxicity to Immune Checkpoint Inhibitors Using Routinely Available Blood and Clinical Markers. Br. J. Cancer 2017, 117, 913–920. [Google Scholar] [CrossRef]
- Iivanainen, S.; Koivunen, J.P. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. Int. J. Mol. Sci. 2020, 21, 556. [Google Scholar] [CrossRef] [Green Version]
- Mountzios, G.; Linardou, H.; Kosmidis, P. Immunotherapy in Non-Small Cell Lung Cancer: The Clinical Impact of Immune Response and Targeting. Ann. Transl. Med. 2016, 4, 268. [Google Scholar] [CrossRef] [Green Version]
- Rounis, K.; Makrakis, D.; Tsigkas, A.-P.; Georgiou, A.; Galanakis, N.; Papadaki, C.; Monastirioti, A.; Vamvakas, L.; Kalbakis, K.; Vardakis, N.; et al. Cancer Cachexia Syndrome and Clinical Outcome in Patients with Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Results from a Prospective, Observational Study. Transl. Lung Cancer Res. 2021, 10, 3538–3549. [Google Scholar] [CrossRef] [PubMed]
- Ravasco, P.; Monteiro-Grillo, I.; Vidal, P.M.; Camilo, M.E. Cancer: Disease and Nutrition Are Key Determinants of Patients’ Quality of Life. Support. Care Cancer 2004, 12, 246–252. [Google Scholar] [CrossRef] [PubMed]
- Sarhill, N.; Mahmoud, F.; Walsh, D.; Nelson, K.A.; Komurcu, S.; Davis, M.; LeGrand, S.; Abdullah, O.; Rybicki, L. Evaluation of Nutritional Status in Advanced Metastatic Cancer. Support. Care Cancer 2003, 11, 652–659. [Google Scholar] [CrossRef] [PubMed]
- Khalid, U.; Spiro, A.; Baldwin, C.; Sharma, B.; McGough, C.; Norman, A.R.; Eisen, T.; O’Brien, M.E.R.; Cunningham, D.; Andreyev, H.J.N. Symptoms and Weight Loss in Patients with Gastrointestinal and Lung Cancer at Presentation. Support. Care Cancer 2007, 15, 39–46. [Google Scholar] [CrossRef] [PubMed]
- Baracos, V.E.; Martin, L.; Korc, M.; Guttridge, D.C.; Fearon, K.C.H. Cancer-Associated Cachexia. Nat. Rev. Dis. Primers 2018, 4, 17105. [Google Scholar] [CrossRef]
- Wakefield, L.M.; Hill, C.S. Beyond TGFβ: Roles of Other TGFβ Superfamily Members in Cancer. Nat. Rev. Cancer 2013, 13, 328–341. [Google Scholar] [CrossRef]
- Cohen, S.; Nathan, J.A.; Goldberg, A.L. Muscle Wasting in Disease: Molecular Mechanisms and Promising Therapies. Nat. Rev. Drug Discov. 2015, 14, 58–74. [Google Scholar] [CrossRef]
- Tisdale, M.J. Are Tumoral Factors Responsible for Host Tissue Wasting in Cancer Cachexia? Future Oncol. 2010, 6, 503–513. [Google Scholar] [CrossRef]
- Argilés, J.M.; Busquets, S.; Stemmler, B.; López-Soriano, F.J. Cancer Cachexia: Understanding the Molecular Basis. Nat. Rev. Cancer 2014, 14, 754–762. [Google Scholar] [CrossRef]
- Coss, C.C.; Clinton, S.K.; Phelps, M.A. Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin. Cancer Res. 2018, 24, 5787–5789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and Classification of Cancer Cachexia: An International Consensus. Lancet Oncol. 2011, 12, 489–495. [Google Scholar] [CrossRef]
- Flint, T.R.; Janowitz, T.; Connell, C.M.; Roberts, E.W.; Denton, A.E.; Coll, A.P.; Jodrell, D.I.; Fearon, D.T. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-Tumor Immunity. Cell Metab. 2016, 24, 672–684. [Google Scholar] [CrossRef]
- Basak, E.A.; Koolen, S.L.W.; Hurkmans, D.P.; Schreurs, M.W.J.; Bins, S.; Oomen de Hoop, E.; Wijkhuijs, A.J.M.; den Besten, I.; Sleijfer, S.; Debets, R.; et al. Correlation between Nivolumab Exposure and Treatment Outcomes in Non–Small-Cell Lung Cancer. Eur. J. Cancer 2019, 109, 12–20. [Google Scholar] [CrossRef] [PubMed]
- Abe, K.; Shibata, K.; Naito, T.; Otsuka, A.; Karayama, M.; Maekawa, M.; Miyake, H.; Suda, T.; Kawakami, J. Impacts of Cachexia Progression in Addition to Serum IgG and Blood Lymphocytes on Serum Nivolumab in Advanced Cancer Patients. Eur. J. Clin. Pharmacol. 2021, 78, 77–87. [Google Scholar] [CrossRef] [PubMed]
- Roch, B.; Coffy, A.; Jean-Baptiste, S.; Palaysi, E.; Daures, J.-P.; Pujol, J.-L.; Bommart, S. Cachexia-Sarcopenia as a Determinant of Disease Control Rate and Survival in Non-Small Lung Cancer Patients Receiving Immune-Checkpoint Inhibitors. Lung Cancer 2020, 143, 19–26. [Google Scholar] [CrossRef]
- Fujii, H.; Makiyama, A.; Iihara, H.; Okumura, N.; Yamamoto, S.; Imai, T.; Arakawa, S.; Kobayashi, R.; Tanaka, Y.; Yoshida, K.; et al. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. Anticancer Res. 2020, 40, 7067–7075. [Google Scholar] [CrossRef]
- Lee, C.-S.; Devoe, C.E.; Zhu, X.; Fishbein, J.S.; Seetharamu, N. Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer. Lung Cancer Manag. 2020, 9, LMT31. [Google Scholar] [CrossRef] [Green Version]
- Nishioka, N.; Uchino, J.; Hirai, S.; Katayama, Y.; Yoshimura, A.; Okura, N.; Tanimura, K.; Harita, S.; Imabayashi, T.; Chihara, Y.; et al. Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J. Clin. Med. 2019, 8, 450. [Google Scholar] [CrossRef] [Green Version]
- Degens, J.H.R.J.; Dingemans, A.C.; Willemsen, A.C.H.; Gietema, H.A.; Hurkmans, D.P.; Aerts, J.G.; Hendriks, L.E.L.; Schols, A.M.W.J. The Prognostic Value of Weight and Body Composition Changes in Patients with Non-small-cell Lung Cancer Treated with Nivolumab. J. Cachexia Sarcopenia Muscle 2021, 12, 657–664. [Google Scholar] [CrossRef]
- Pressoir, M.; Desné, S.; Berchery, D.; Rossignol, G.; Poiree, B.; Meslier, M.; Traversier, S.; Vittot, M.; Simon, M.; Gekiere, J.P.; et al. Prevalence, Risk Factors and Clinical Implications of Malnutrition in French Comprehensive Cancer Centres. Br. J. Cancer 2010, 102, 966–971. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de van der Schueren, M.A.E.; Laviano, A.; Blanchard, H.; Jourdan, M.; Arends, J.; Baracos, V.E. Systematic Review and Meta-Analysis of the Evidence for Oral Nutritional Intervention on Nutritional and Clinical Outcomes during Chemo(Radio)Therapy: Current Evidence and Guidance for Design of Future Trials. Ann. Oncol. 2018, 29, 1141–1153. [Google Scholar] [CrossRef] [PubMed]
- Schiessel, D.L.; Baracos, V.E. Barriers to Cancer Nutrition Therapy: Excess Catabolism of Muscle and Adipose Tissues Induced by Tumour Products and Chemotherapy. Proc. Nutr. Soc. 2018, 77, 394–402. [Google Scholar] [CrossRef] [PubMed]
- Meuric, J.; Besnard, I. Nutrition chez le patient adulte atteint de cancer: Quand doit-on proposer un conseil diététique personnalisé ? Nutr. Clin. Métab. 2012, 26, 197–218. [Google Scholar] [CrossRef]
- Senesse, P.; Bachmann, P.; Bensadoun, R.J.; Besnard, I.; Bourdel-Marchasson, I.; Bouteloup, C.; Crenn, P.; Goldwasser, F.; Guérin, O.; Latino-Martel, P.; et al. Nutrition chez le patient adulte atteint de cancer: Textes courts. Nutr. Clin. Métab. 2012, 26, 151–158. [Google Scholar] [CrossRef]
- Muscaritoli, M.; Arends, J.; Aapro, M. From Guidelines to Clinical Practice: A Roadmap for Oncologists for Nutrition Therapy for Cancer Patients. Ther. Adv. Med. Oncol. 2019, 11, 1758835919880084. [Google Scholar] [CrossRef] [Green Version]
- van der Werf, A.; Langius, J.A.E.; Beeker, A.; ten Tije, A.J.; Vulink, A.J.; Haringhuizen, A.; Berkhof, J.; van der Vliet, H.J.; Verheul, H.M.W.; de van der Schueren, M.A.E. The Effect of Nutritional Counseling on Muscle Mass and Treatment Outcome in Patients with Metastatic Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. Clin. Nutr. 2020, 39, 3005–3013. [Google Scholar] [CrossRef]
- Cereda, E.; Cappello, S.; Colombo, S.; Klersy, C.; Imarisio, I.; Turri, A.; Caraccia, M.; Borioli, V.; Monaco, T.; Benazzo, M.; et al. Nutritional Counseling with or without Systematic Use of Oral Nutritional Supplements in Head and Neck Cancer Patients Undergoing Radiotherapy. Radiother Oncol. 2018, 126, 81–88. [Google Scholar] [CrossRef]
- Ravasco, P.; Monteiro-Grillo, I.; Vidal, P.M.; Camilo, M.E. Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy. J. Clin. Oncol. 2005, 23, 1431–1438. [Google Scholar] [CrossRef]
- Blackwood, H.A.; Hall, C.C.; Balstad, T.R.; Solheim, T.S.; Fallon, M.; Haraldsdottir, E.; Laird, B.J. A Systematic Review Examining Nutrition Support Interventions in Patients with Incurable Cancer. Support. Care Cancer 2020, 28, 1877–1889. [Google Scholar] [CrossRef]
- Gomes, F.; Baumgartner, A.; Bounoure, L.; Bally, M.; Deutz, N.E.; Greenwald, J.L.; Stanga, Z.; Mueller, B.; Schuetz, P. Association of Nutritional Support With Clinical Outcomes Among Medical Inpatients Who Are Malnourished or at Nutritional Risk: An Updated Systematic Review and Meta-Analysis. JAMA Netw. Open 2019, 2, e1915138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bachmann, P.; Bertrand, A.; Roux, P. Prise en charge nutritionnelle dans les parcours de soins des cancers. Nutr. Clin. Métab. 2016, 30, 399–408. [Google Scholar] [CrossRef]
- Cortellini, A.; Bersanelli, M.; Buti, S.; Cannita, K.; Santini, D.; Perrone, F.; Giusti, R.; Tiseo, M.; Michiara, M.; Marino, P.D.; et al. A Multicenter Study of Body Mass Index in Cancer Patients Treated with Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors: When Overweight Becomes Favorable. J. Immunother. Cancer 2019, 7, 57. [Google Scholar] [CrossRef] [PubMed]
- Dewys, W.D.; Begg, C.; Lavin, P.T.; Band, P.R.; Bennett, J.M.; Bertino, J.R.; Cohen, M.H.; Douglass, H.O.; Engstrom, P.F.; Ezdinli, E.Z.; et al. Prognostic Effect of Weight Loss Prior Tochemotherapy in Cancer Patients. Am. J. Med. 1980, 69, 491–497. [Google Scholar] [CrossRef]
- Hu, Y.; Shen, J.; Liu, R.; Feng, Z.; Zhang, C.; Ling, L.; Chen, L. Prognostic Value of Pretreatment Prognostic Nutritional Index in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int. J. Biol. Markers 2018, 33, 372–378. [Google Scholar] [CrossRef] [Green Version]
- Yan, L.; Nakamura, T.; Casadei-Gardini, A.; Bruixola, G.; Huang, Y.-L.; Hu, Z.-D. Long-Term and Short-Term Prognostic Value of the Prognostic Nutritional Index in Cancer: A Narrative Review. Ann. Transl. Med. 2021, 9, 1630. [Google Scholar] [CrossRef]
Characteristic | Mean (SD) | n (%) |
---|---|---|
Sex Men Women | 71 (56) 56 (44) | |
Age at diagnosis | 67 (8) | |
BMI | 23.7 (4.4) | |
Stage 2 3 4 | 1 (0.8) 9 (7.1) 117 (92) | |
PS at inclusion 0 1 2 | 33 (26) 81 (64) 13 (10) | |
PD-L1 a >1% ≤1% | 12 (57) 9 (43) | |
Number of metastatic sites 0 1 2 3 4 or more | 9 (7.1) 32 (26) 42 (33.1) 25 (19.7) 19 (15) | |
Smoking No Actual Previous | 15 (12) 18 (14) 94 (74) | |
COPD Yes No | 23 (18) 104 (82) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gouez, M.; Delrieu, L.; Bouleuc, C.; Girard, N.; Raynard, B.; Marchal, T. Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. Cancers 2022, 14, 3439. https://doi.org/10.3390/cancers14143439
Gouez M, Delrieu L, Bouleuc C, Girard N, Raynard B, Marchal T. Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. Cancers. 2022; 14(14):3439. https://doi.org/10.3390/cancers14143439
Chicago/Turabian StyleGouez, Manon, Lidia Delrieu, Carole Bouleuc, Nicolas Girard, Bruno Raynard, and Timothée Marchal. 2022. "Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study" Cancers 14, no. 14: 3439. https://doi.org/10.3390/cancers14143439
APA StyleGouez, M., Delrieu, L., Bouleuc, C., Girard, N., Raynard, B., & Marchal, T. (2022). Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. Cancers, 14(14), 3439. https://doi.org/10.3390/cancers14143439